The Incidence of Adverse Drug Reactions in Patients Treated with Statins in the Emirates: A Retrospective Cohort Study.
Adult
Aged
Cardiovascular Diseases
/ diagnosis
Databases, Factual
Drug-Related Side Effects and Adverse Reactions
/ diagnosis
Dyslipidemias
/ diagnosis
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/ adverse effects
Incidence
Male
Middle Aged
Retrospective Studies
Risk Assessment
Risk Factors
Time Factors
United Arab Emirates
/ epidemiology
Young Adult
Middle East
Statin
adverse drug reactions
drug safety
hyperlipidaemia
incidence.
Journal
Current vascular pharmacology
ISSN: 1875-6212
Titre abrégé: Curr Vasc Pharmacol
Pays: United Arab Emirates
ID NLM: 101157208
Informations de publication
Date de publication:
2020
2020
Historique:
received:
11
11
2018
revised:
14
03
2019
accepted:
29
03
2019
pubmed:
10
4
2019
medline:
29
9
2020
entrez:
10
4
2019
Statut:
ppublish
Résumé
We investigated the incidence of adverse drug reactions (ADRs) in patients treated with statins for cardiovascular (CV) risk among the United Arab Emirates (UAE) population. This is a retrospective cohort study conducted among statin users attending 2 tertiary care centres: Al Ain and Tawam hospitals in Al Ain city, UAE. We retrieved the clinical profile of all the patients taking statins from January 2011 to January 2015 using our electronic database (Cerner®). Among 556 patients (418 men; 138 women) taking statins, 237 ADRs were reported (186 men; 51 women). The incidence of ADRs was 40.7%, and was more frequent among patients at "high CV disease (CVD) risk" and "moderate CVD risk" than other risk categories. High CVD risk (odds ratio, 1.67; 95% confidence interval [CI], 1.19-2.34), vitamin D deficiency 1.45 (95% CI, 0.89-2.38), type 2 diabetes 1.22 (95% CI, 0.84-1.77) and hypertension 1.13 (95% CI, 0.70-1.83) are some of the factors that were associated with statin ADRs. The incidence of ADRs among statin users was 42.6%, and frequent ADRs (49%) were noted in patients with high CVD risk. Early identification of these ADRs should improve patient adherence to life-saving statin treatment.
Identifiants
pubmed: 30963975
pii: CVP-EPUB-97925
doi: 10.2174/1570161117666190408164908
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
193-199Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.